Industry body aims to strengthen policy advocacy, innovation, and global competitiveness of India's fast-growing CRDMO sector
Deploys $40 million in Hyderabad; advances APIs, peptides, and global small molecule capabilities
This collaboration sets the stage for WuXi Biologics’ first integrated CRDMO center in the region
His career spans notable tenures at Syngene International Limited, Cipla, Nestlé, and Bharat Petroleum Corporation Limited
Eleven CRDMOs collaborate to form IPSO with the aim to elevate India’s position in the global pharmaceutical value-chain
The CRDMO site will add 120,000L manufacturing capacity to WuXi Biologics’ global network
Enhanced CMC infrastructure at Cranbury site aims to improve bioavailability, streamline formulation development and support faster progression of challenging drug candidates into clinical trials
Anti-GD2 monoclonal antibody for high-risk neuroblastoma advances toward BLA submission following successful tech transfer from California to Bengaluru
Q4FY26 revenue climbs 19% to Rs. 2,290 crore as CDMO sterile injectables, radiopharma and generics businesses drive growth momentum
Subscribe To Our Newsletter & Stay Updated
